{"filings":[{"id":3550320,"accession_number":"0001437749-26-032969","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-10-20T11:00:28+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Moleculin Biotech sets 1-for-20 reverse split effective Oct 20, 2026; shares outstanding fall to ~1.05M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved 1-for-20 reverse split after stockholders authorized a ratio of 1-for-2 to 1-for-20 at the Oct 9, 2026 annual meeting.","Split effective 12:01 a.m. ET Oct 20, 2026; MBRX trades post-split on Nasdaq Capital Market with new CUSIP 60855D507.","Outstanding shares drop from ~20.91 million to ~1.05 million; authorized shares stay at 500 million; par value unchanged at $0.001.","No fractional shares issued — holders receive cash equal to the fraction times the 5-day average closing price before the split.","Restated post-split FY2025 net loss per share $(568.38) vs pre-split $(28.42); net loss $33.56M in FY2025 vs $26.05M in FY2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3495996,"accession_number":"0001437749-26-032762","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-10-16T13:29:32+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin Biotech furnishes Oct 16, 2026 investor presentation under Reg FD; exhibit text not included","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Moleculin Biotech (MBRX) disclosed a corporate investor presentation dated October 16, 2026 as Exhibit 99.1 under Item 7.01 Regulation FD.","Filing states the presentation is posted on the Company's website, but the exhibit supplied contains no readable content beyond the 'Exhibit 99.1' header.","No financial results, clinical trial data, guidance, or transaction terms appear anywhere in the filing body; no specific facts can be extracted.","Signed by Jonathan P. Foster on October 16, 2026; company address listed as 5300 Memorial Drive, Suite 950, Houston, TX 77007."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3375881,"accession_number":"0001437749-26-032455","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-10-09T21:15:50+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Moleculin shareholders approve reverse split authority up to 1-for-20; supermajority removal fails","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved board authority for a reverse stock split at a ratio of 1-for-2 to 1-for-20, exercisable before the one-year anniversary of the Oct. 9, 2026 annual meeting.","Amendment to eliminate supermajority charter-voting requirements failed, falling short of the required two-thirds of outstanding shares (2,828,497 for, 901,488 against).","Stockholders approved an amendment to the 2024 Stock Plan adding 3,861,894 shares; the 8-K states 3,875,999 shares total authorized for issuance.","Re-elected directors Walter V. Klemp, Robert E. George, Michael D. Cannon, John Climaco and Elizabeth A. Cermak; Grant Thornton LLP ratified as auditor for fiscal 2026 and say-on-pay passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3246999,"accession_number":"0001437749-26-031978","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-10-05T12:30:21+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin Biotech 8-K cites Oct 5, 2026 investor presentation; exhibit content not included","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Moleculin Biotech (MBRX) said it is using an attached corporate presentation posted on its website, dated October 5, 2026, per the filing signed by Jonathan P. Foster.","Exhibit 99.1 contains no presentation text, slides, data tables, or figures - only the exhibit title - so no clinical, pipeline, or financial updates are available in this filing.","No earnings, guidance, trial results, financing terms, or partnership details appear anywhere in the filing body or the appended exhibit.","Investors seeking the actual corporate presentation content must retrieve it directly from the company's website; it cannot be summarized from this document."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3136038,"accession_number":"0001437749-26-031419","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-09-29T12:45:26+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin Biotech completes Part A enrollment in Phase 2/3 MIRACLE trial with 89 R/R AML subjects","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Part A of the pivotal Phase 2/3 MIRACLE trial closed enrollment with 89 subjects enrolled and one additional subject in screening.","Moleculin remains on track for a comprehensive Part A data readout in Q1 2027.","The full Part A population is expected to be approximately 50/50 between 1L 7+3 and venetoclax-based regimens, versus a 70/30 split in the first 45 subjects.","CEO Walter Klemp said the Q1 2027 readout will be deeper in data than the first interim n45 readout.","The company continues to see no cardiotoxicity in blinded MIRACLE data; AnnAraC combines Annamycin with cytarabine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3110438,"accession_number":"0001437749-26-031280","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-09-28T11:00:14+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin publishes peer-reviewed Annamycin cardiac safety analysis: no cardiotoxicity in 90 patients across 5 trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pooled analysis of 5 trials (3 AML, 2 metastatic STS): 90 patients treated, paired echocardiographic data for 78; mean LVEF 60.6% at baseline vs 60.0% post-treatment (p=0.84).","No association between cumulative Annamycin dose or patient age and LVEF change; serial ECGs, troponin I/T and global longitudinal strain showed no treatment-related cardiotoxicity.","Median cumulative Annamycin dose was 660 mg/m2, exceeding conventional anthracycline lifetime limits; analysis independently reviewed by a Cleveland Clinic cardio-oncology laboratory.","CEO Walter Klemp said the absence of detectable cardiac toxicity beyond traditional dose thresholds supports continued development of Annamycin as a potentially safer anthracycline.","Annamycin is currently being evaluated in Moleculin's MIRACLE clinical development program for relapsed or refractory AML."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3092076,"accession_number":"0001437749-26-031199","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-09-25T17:05:32+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin preclinical data: Annamycin pancreatic cancer activity partly mediated by CD8+ T cells","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preclinical data: Annamycin's pancreatic cancer activity is partially mediated by CD8+ T cells, suggesting an immune-mediated mechanism beyond direct cytotoxicity.","Data presented at AACR Conference on Pancreatic Cancer, Sept 25–28, 2026, at Hilton San Diego Bayfront; abstract published in Sept 15, 2026 Cancer Research supplement.","Presenter: Angela T. Alistar, MD (Morristown Medical Center, Atlantic Health System / Carol G. Simon Cancer Center); abstract title: 'Turning cold pancreatic tumors hot'.","Annamycin is not currently in clinical development for pancreatic cancer; lead program remains MIRACLE trial in relapsed/refractory AML, the basis of near-term milestones.","CEO Walter Klemp: data point to 'unexpected additional benefit'; if observation holds, it broadens where Annamycin might be useful and how it might be combined."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":3027756,"accession_number":"0001437749-26-031005","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-09-23T12:25:34+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Moleculin secures Mexican patent for lung-targeted liposomal Annamycin through 2040","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mexican Patent Office granted Patent No. 436849 for lung-targeted liposomal Annamycin; expires Nov 23, 2040.","Patent strengthens global IP for Annamycin, now in pivotal MIRACLE trial for relapsed/refractory AML.","Issued 888,400 shares via ATM in Sept 2026 for $0.48M gross proceeds; shares outstanding now 20,385,780.","Series I warrant exercise price reduced from $0.75 to $0.51 per share due to anti-dilution after ATM issuance.","CEO Walter Klemp cites patent as reinforcing long-term commercial potential of Annamycin platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2963596,"accession_number":"0001437749-26-030757","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-09-18T21:00:57+00:00","items":["3.01"],"status":"ready","headline":"Moleculin Biotech receives Nasdaq delisting notice; bid price below $1 for 30 days","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Moleculin on Sept 15, 2026 that common stock failed minimum bid price ($1) from July 31 to Sept 11, 2026.","Company ineligible for 180-day cure period due to 1-for-25 reverse stock split effected Dec 1, 2025.","Company will request a hearing before Nasdaq Hearings Panel; trading continues pending panel decision.","No assurance of continued listing; risk of suspension or delisting if hearing fails."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2852679,"accession_number":"0001437749-26-030315","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-09-14T20:00:15+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin to present new Annamycin data at AACR pancreatic cancer conference and two European scientific meetings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three September 2026 presentations examine Annamycin tissue distribution, topoisomerase II inhibition, and CD8+ T cell-mediated antitumor activity.","Presentations include Sept 25-28 AACR Pancreatic Cancer Conference in San Diego, plus Polish meetings on Sept 9-12 and Sept 14.","Waldemar Priebe (MD Anderson) presents two talks; Angela Alistar (Atlantic Health) presents AACR abstract on pancreatic cancer.","MIRACLE trial in relapsed/refractory AML remains the primary development focus and basis of near-term milestones.","AACR abstract under embargo until publication on Sept 25, 2026 at 1:00 p.m. ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2579196,"accession_number":"0001437749-26-029336","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-08-31T21:15:01+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin Biotech posts investor presentation; no material financial or clinical details disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Corporate presentation dated August 31, 2026 published on company website.","No revenue, earnings, clinical trial outcomes, or guidance figures provided in filing text.","Materiality low; presentation content not reproduced in the 8-K submission.","Ticker MBRX; presentation furnished under Regulation FD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2253958,"accession_number":"0001437749-26-027835","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-08-14T12:30:19+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moleculin Q2 2026: MIRACLE CR rates 3x control, cash runway into Q1 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MIRACLE interim data: CR 43% (190 mg/m²) and 36% (230 mg/m²) vs 12% control; CRc 50% and 57% vs 29%.","Enrollment >80% of 90 patients; data readout Dec 2026-Feb 2027; Part B start 1H 2027.","Cash $7.3M at June 30 plus $9.3M raised post-quarter; runway into Q1 2027.","R&D expenses $5.5M in Q2 2026 vs $3.6M YoY; G&A flat at $2.1M.","No cardiotoxicity observed; ASCO data support cardiac safety profile."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2026598,"accession_number":"0001437749-26-025474","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-08-03T21:11:51+00:00","items":["1.01","9.01"],"status":"ready","headline":"Moleculin Biotech raises ~$9.3M in public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$9.3M from sale of 12.4M shares and warrants at $0.75 per unit.","Warrants exercisable at $0.75 for five years; pre-funded warrants at $0.001.","Proceeds to fund Annamycin clinical development and working capital.","Lock-up agreements for officers/directors for 60 days; 45-day ban on further equity issuances.","Placement agent fees: 6.5% to Roth Capital, 1% to Maxim Group."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1977522,"accession_number":"0001437749-26-025167","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-07-31T12:00:12+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin reports 37% blinded CRc in MIRACLE trial; venetoclax-failed subgroup similar","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary blinded CRc of 37% and CR of 24% in 62 evaluable R/R AML subjects.","Among 30 patients who failed prior venetoclax, CRc also 37% (3x published salvage rate of ~13%).","No cardiotoxicity observed; enrollment at 74 of 90; final Part A treatment expected Sept 2026.","Unblinded Part A results expected Dec 2026–Feb 2027; prior unblinded Annamycin arms showed CRc 50-57% vs control 29%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1343120,"accession_number":"0001437749-26-022088","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-06-30T12:30:18+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin reports Annamycin CR rates 3x control in Phase 2/3 MIRACLE interim","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CR of 43% and 36% for Annamycin arms vs 12% control; CRc 50% and 57% vs 29% control (n=45, ITT).","iDMC unanimously recommended continuing; no statistical significance at interim per O'Brien-Fleming design.","Part A enrollment 67 of 90 (74%); trial remains powered at 80% for final analysis of ~282 subjects.","Results after single cycle; 75.6% of patients over 60, 31.1% pretreated with venetoclax."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1343122,"accession_number":"0001437749-26-022087","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-06-30T12:29:53+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Moleculin Biotech reports warrant exercise for $2.7M; shares outstanding rise to 7.07M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Warrants to purchase 1,361,500 shares exercised, generating gross proceeds of ~$2.7 million.","As of June 29, 2026, common shares outstanding total 7,065,000.","Corporate presentation posted on company website; no material updates disclosed in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":870916,"accession_number":"0001437749-26-019660","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-06-05T12:30:10+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin announces strong physician intent to prescribe Annamycin in R/R AML; likelihood-to-prescribe score 6/7","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Oncologists reported average likelihood-to-prescribe Annamycin of 6 out of 7, citing deep remissions and reduced cardiotoxicity.","Physicians highlighted Annamycin's biomarker-agnostic applicability and potential to bridge patients to bone marrow transplant.","Payers viewed Annamycin as a potentially valuable addition for R/R AML, driven by efficacy and safety profile.","Key differentiators include MRD-negative responses and reduced cardiotoxicity, especially important for pediatric and repeat dosing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":733236,"accession_number":"0001437749-26-018819","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-05-29T13:26:14+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin ASCO data: Annamycin shows no cardiotoxicity at high cumulative doses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pooled analysis of 90 patients: no significant LVEF change (mean diff -0.12%, p=0.84) across doses up to 2,970 mg/m².","Independent Cleveland Clinic review confirms no drug-induced cardiotoxicity across ECGs, biomarkers, and adverse events.","Phase 1b/2 AML study achieved 50% CR, 60% CRc, median overall survival 12.39 months; 50% of responders received transplant.","Pivotal Phase 2b/3 MIRACLE trial unblinding of first 45 patients on track for June 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":649804,"accession_number":"0001437749-26-018317","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-05-26T12:00:24+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin posts corporate presentation on website; no new material details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated May 2026 made available on company website.","No financial results, clinical updates, or guidance provided in the filing.","Presentation content is an image exhibit; no specific data extracted.","This is a routine disclosure; no material changes to company outlook."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":609119,"accession_number":"0001437749-26-018242","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-05-22T20:00:36+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin Biotech ASCO abstract on Annamycin cardiac safety shows no cardiotoxicity in 90 patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Abstract accepted for poster at 2026 ASCO Annual Meeting (May 29–June 2, Chicago).","Pooled safety analysis of 90 Annamycin patients; median cumulative dose 660 mg/m2.","No significant LVEF change from baseline (mean diff -0.12%, p=0.84); no dose correlation.","CEO highlights potential to provide anthracycline therapy without cardiotoxicity limits.","Company's Phase 1b/2 AML study previously showed 50% CR and median OS of 12.39 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":452965,"accession_number":"0001437749-26-017226","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-05-15T12:30:15+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moleculin Q1: Cash $10.3M; MIRACLE trial 40% CRc; 45 subjects enrolled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $10.3M as of March 31, 2026; R&D expense $5.4M (up $2.0M YoY) on MIRACLE trial costs.","MIRACLE Phase 2B/3 trial: first 45 subjects enrolled; blinded composite complete remission (CRc) rate of 40%.","First interim unblinding expected June 2026; 90th subject recruitment targeted for Q3 2026.","Completed Q1 2026 financings with ~$8.3M gross proceeds; runway extended into Q3 2026.","Expect to start pancreatic cancer trial in 2H 2026; aiming for rolling NDA submission for R/R AML in 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":50402,"accession_number":"0001437749-26-016535","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-05-13T12:00:58+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin reports preliminary blinded CR rate ~30% in MIRACLE trial; first unblinding before June 30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary blinded CRc >40%, CR ~30% vs. historical ~17-18% for cytarabine alone.","First unblinding of 45-subject data expected before June 30, 2026; ~30 Annamycin + cytarabine vs 15 control.","56 of 90 subjects recruited in Part A as of May 1, 2026; on track for Q3 2026 completion.","Over 30% of subjects are R/R to prior venetoclax regimen, a challenging population.","Annamycin has FDA Fast Track and Orphan Drug Designations for R/R AML."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":24401,"accession_number":"0001437749-26-016260","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-05-12T13:30:19+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin reports Annamycin shows no clinically significant cardiotoxicity in 90-patient pooled analysis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pooled analysis of 90 R/R AML patients across 5 trials; 78 had source-verified pre/post ejection fraction assessments.","No patients met criteria for clinically significant left ventricular dysfunction; mean ejection fraction stable.","Cardiac safety review conducted by Cleveland Clinic cardio-oncology laboratory.","Data presented at EHA 2026 Congress; Annamycin dosed beyond conventional anthracycline lifetime limits.","Management believes results support broader positioning in AML and other oncology indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94490,"accession_number":"0001437749-26-015762","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin Biotech secures Hong Kong patent for liposomal Annamycin through 2040","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Hong Kong patent No. 40073244 covers proprietary reconstitution method of liposomal Annamycin, expiring June 25, 2040.","Invention jointly owned with The University of Texas System; extends IP protection across four continents.","Company expects first Phase 3 clinical data release for Annamycin later this quarter.","Existing granted/allowed patents include US, Australia, Canada, China, Europe, India, Israel, Japan, Mexico, Singapore, Taiwan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94489,"accession_number":"0001437749-26-013083","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin's Annamycin extends survival >60% in metastatic pancreatic cancer preclinical models at AACR 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median survival 29 days vs 18 days (p=0.0003) in metastatic PDAC models.","Significant tumor volume reduction across multiple PDAC models (p<0.001).","Higher tumor/pancreatic accumulation vs doxorubicin (p<0.0001).","Induced CD8+ and CD4+ T-cell infiltration, suggesting immune activation.","No cardiotoxicity observed; supports Annamycin's differentiated safety profile."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94488,"accession_number":"0001437749-26-012325","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Shareholders approve issuance of up to 6.4M warrant shares; name change rejected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved issuance of up to 6,367,956 shares upon exercise of warrants issued Feb 20, 2026.","Name change to Moleculin Inc. failed; received 2,015,174 'For' votes but needed majority of 4,933,110 outstanding shares.","Adjournment proposal passed to allow further proxy solicitation if needed.","A total of 2,382,989 shares were present at the Special Meeting, constituting a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106915,"accession_number":"0001437749-26-009298","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin enrolls 45th subject in MIRACLE AML trial; interim data unblinding on track for mid-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["45th subject enrolled in pivotal Phase 2B/3 MIRACLE trial of Annamycin + cytarabine (AnnAraC) for R/R AML.","Interim unblinding of first 45 subjects remains on track for mid-2026; CEO calls it potentially the most important data moment.","Early blinded data among first 30 patients showed 40% composite complete remission rate (30% CR, 10% CR with partial hematologic recovery).","Approximately 35% of subjects had previously failed venetoclax-based therapies; many had adverse genetic markers.","Enrollment progressing toward 90-subject Part A completion expected in Q3 2026; Phase 3 design to follow dose determination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106914,"accession_number":"0001437749-26-008951","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin Biotech posts investor presentation; no material new information","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation furnished under Item 7.01 on March 19, 2026.","No financial results, operational updates, or guidance provided in the filing.","Presentation is not incorporated by reference into SEC filings.","Exhibit 99.1 is an image exhibit with no extractable text or data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106913,"accession_number":"0001437749-26-008949","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Moleculin reports FY2025 results; MIRACLE trial shows 40% blinded CRc rate in first 30 R/R AML patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 R&D expense $15.9M (down from $17.7M), G&A $9.2M; cash $8.9M at year-end; $8.3M raised in Q1 2026; cash runway into Q3 2026.","MIRACLE trial (Phase 2B/3) Annamycin + cytarabine in R/R AML: blinded CRc 40% in first 30 subjects; interim unblinding for 45 patients expected mid-2026.","Pipeline progress: WP1066 Phase 1 pediatric brain tumor trial shows safety and immune response; Annamycin GBM collaboration and pancreatic cancer study initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106912,"accession_number":"0001437749-26-004800","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Moleculin Biotech raises ~$8.3M via warrant exercise inducement; issues new Series H warrants for 6.4M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders exercise 2,122,652 existing warrants at $3.90 per share; gross proceeds ~$8.3M.","Company issues new Series H warrants for up to 6,367,956 shares (300% of exercised) with 5-year term.","New warrant exercise price = lesser of $3.90 or lowest VWAP in 5 trading days post-announcement; floor $0.962.","Shareholder approval required for issuance of new warrant shares; resale registration to be filed by March 31, 2026.","Roth Capital served as financial advisor, receiving 7% of gross proceeds from the warrant exercise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106911,"accession_number":"0001437749-26-004558","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin posts new investor presentation on website","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed under Item 7.01 as Regulation FD disclosure with Exhibit 99.1.","Presentation is dated February 2026; actual content is an image exhibit not parsed.","No specific financial, clinical, or operational data disclosed in the 8-K text.","Investors should review the presentation on the company's website for details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106910,"accession_number":"0001437749-26-004455","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin reports 40% blinded CRc in MIRACLE trial; 35 subjects treated, unblinding on track for Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary blinded composite CR rate of 40% (30% CR, 10% CRh) in first 30 subjects; 67% above historical cytarabine CR.","35 subjects treated to date with 11 in screening; targeting first unblinding at 45 subjects, on track for Q1 2026 treatment milestone.","Roughly 35% of treated subjects are venetoclax regimen failures, a challenging population with high unmet need.","Continued absence of cardiotoxicity cited; Annamycin holds FDA Fast Track and Orphan Drug Designation for R/R AML."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106909,"accession_number":"0001437749-26-004236","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin gets Japanese patent allowance for Annamycin reconstitution methods","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Japan Patent Office issued notice of allowance for Patent App. 2021-577862 covering liposomal Annamycin preparation methods.","Patent expected to issue in coming months; complements existing US and European Annamycin patents.","Annamycin (naxtarubicin) is in Phase 3 for relapsed/refractory AML with FDA Fast Track and Orphan Drug designations.","CEO Klemp states the allowance strengthens international IP for non-cardiotoxic anthracycline therapy.","Additional Annamycin-related patent applications are pending in major jurisdictions worldwide."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106908,"accession_number":"0001437749-26-003119","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Moleculin Biotech shareholders approve warrant share issuance, reject name change to Moleculin Inc.","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Approved issuance of up to 2,610,823 shares upon exercise of warrants issued Dec 11, 2025; 578,385 For, 68,176 Against.","Name change amendment from Moleculin Biotech, Inc. to Moleculin Inc. failed: 1,124,921 For (needed >1,346,766 majority of outstanding shares).","Adjournment proposal approved (582,534 For, 64,190 Against) to allow further proxy solicitation if needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106907,"accession_number":"0001437749-26-001484","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin Biotech posts corporate presentation on website; no material new details disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company furnished investor presentation dated January 2026 as Exhibit 99.1.","Presentation posted on company website under Item 7.01 Regulation FD disclosure.","No specific financial or clinical updates provided in the filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106906,"accession_number":"0001437749-26-001140","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin reports no cardiotoxicity in 90 Annamycin subjects across five trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Independent expert review of 90 subjects across five clinical trials found no evidence of cardiotoxicity.","65 of 90 subjects received cumulative doses above FDA lifetime max of 550 mg/m2; one exceeded 6,500 mg/m2.","Data reviewed included serial ECGs, echocardiography with global longitudinal strain, and cardiac troponins.","Trials covered acute myeloid leukemia and soft tissue sarcoma, both as monotherapy and with cytarabine.","CEO cites potential for Annamycin to become first non-cardiotoxic anthracycline addressing high unmet need."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106905,"accession_number":"0001437749-26-001050","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin: MIRACLE trial unblinding on track for Q1 2026; global expansion to 9 countries","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First unblinding of 45 subjects in pivotal Phase 2B/3 MIRACLE trial for 2L AML expected Q1 2026.","Trial expanded to 9 countries with over 46 sites selected; next unblinding of 90 subjects expected Q3 2026.","Atlantic Health to fund IIT with Annamycin in 3L pancreatic cancer; preclinical data show activity.","WP1066 Phase 2 GBM trial at Northwestern continues; Emory to start pediatric brain tumor trial in 2H 2026.","Non-cardiotoxicity review of Annamycin data to be presented Q1 2026; potential first non-cardiotoxic anthracycline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106904,"accession_number":"0001437749-26-000695","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Moleculin Biotech regains Nasdaq compliance, avoiding delisting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq staff notified Panel on Jan 6, 2026 that Moleculin regained compliance with Listing Rule 5550(b)(1) (min $2.5M equity).","Company received delist determination on Nov 20, 2025 and had appealed; hearing now cancelled.","Company is in compliance with all applicable Nasdaq continued listing standards as of Jan 6, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123237,"accession_number":"0001437749-25-038478","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Moleculin Biotech Reduces Warrant Exercise Price to $3.90, Boosts Equity Above $10M to Address Nasdaq Delisting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Entered warrant amendment agreements on Dec 21, 2025 reducing exercise price of Series E, F, G warrants to $3.90 per share.","Amended Series E and F warrants to delete certain anti-dilution provisions and modify Black Scholes Value definition.","Received Nasdaq delisting notice on Nov 20, 2025 for non-compliance with $2.5M equity rule; appealed and hearing set for Jan 20, 2026.","Raised $6.8M from warrant exercise on Dec 9, 2025 and $1.1M from ATM facility; stockholders' equity now exceeds $10.0M.","Panel hearing for Nasdaq appeal scheduled for January 20, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123236,"accession_number":"0001437749-25-038079","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin reports positive Phase 1 results for WP1066 in pediatric malignant brain tumors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["WP1066 showed no significant toxicity and determined maximum feasible dose in 10 children with high-grade glioma.","Partial tumor response observed in a DIPG patient; anti-tumor immune responses demonstrated via STAT3 suppression.","Results published in Journal of Clinical Investigation Insight; Phase 2 trial warranted based on findings.","Compassionate use in 3 additional children with high-grade glioma also evaluated.","Study funded by Peach Bowl LegACy Fund and CURE Childhood Cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123235,"accession_number":"0001437749-25-038047","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Moleculin Biotech regains Nasdaq bid price compliance after stock closes at $1.00+ for 10 days","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq confirmed compliance with Listing Rule 5550(a)(2) effective Dec 15, 2025.","Cure based on closing bid price at or above $1.00 for 10 consecutive days ending Dec 12.","Previous deficiency notice from June 27, 2025 is now closed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123234,"accession_number":"0001437749-25-037414","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Moleculin Biotech raises ~$6.8M via warrant exercise inducement, issues new Series G warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered inducement letters with holders of Series C/D/F warrants to exercise at $6.63 or $6.3219 per share.","Company expects aggregate gross proceeds of up to ~$6.8M from the warrant exercises.","In exchange, issues new Series G warrants to purchase up to 2,610,823 shares (250% of exercised shares) at $6.63, exercisable upon shareholder approval, 5-year term.","New warrants include anti-dilution price reset with a floor of $1.326 per share and cashless exercise feature.","Company to file resale registration statement for Series G warrant shares by Jan 8, 2026, seek SEC effectiveness by Feb 9, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123233,"accession_number":"0001437749-25-037209","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin reports MIRACLE AML trial enrollment at 78% of 45-subject interim target","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrollment increased to 78% of target for first interim unblinding (up from 60% in Nov).","First unblinding will involve 45 subjects; treatment completion expected Q1 2026.","Consented subjects across seven countries; recruitment ongoing beyond the 78% mark.","Part A of trial (90 subjects) expected to complete enrollment in H1 2026.","Blinded response activity tracking within expected range per CEO commentary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123232,"accession_number":"0001437749-25-037084","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin partners with CIC biomaGUNE for preclinical Annamycin glioblastoma study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement supplies Annamycin for investigator-initiated preclinical research at CIC biomaGUNE, Spain.","Studies compare intra-arterial L-Annamycin and Free-Annamycin vs Doxil and free doxorubicin in mouse GBM models.","Principal investigator Jesús Ruiz-Cabello to lead the evaluation of tumor progression.","Annamycin holds FDA Fast Track and Orphan Drug Designation for AML and STS lung metastases.","GBM is the most common malignant brain tumor with median survival of 15 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123231,"accession_number":"0001437749-25-036488","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-11-28T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Moleculin Biotech announces 1-for-25 reverse stock split effective Dec 1, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1:25 ratio effective 12:01 a.m. ET on December 1, 2025.","Outstanding shares reduced from ~51.6M to ~2.07M; authorized shares remain at 500M.","Series E and F warrants have potential exercise price adjustments based on VWAP.","No fractional shares issued; cash paid in lieu of fractional interests.","Ticker MBRX unchanged; new CUSIP number 60855D408."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123230,"accession_number":"0001437749-25-036082","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-11-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin Biotech furnishes November 2025 corporate presentation; content not disclosed in filing text","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing under Item 7.01: corporate presentation posted on company website as Exhibit 99.1.","Presentation date: November 2025. No specific financial or operational data included in the filing.","Company ticker: MBRX (NASDAQ). No changes in guidance, earnings, or leadership disclosed.","Given absence of presentation content, material impact cannot be assessed from this filing alone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123229,"accession_number":"0001437749-25-036006","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Moleculin Biotech receives Nasdaq delisting notice for non-compliance with equity rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received delist determination letter on Nov 20, 2025 for failing to meet $2.5M minimum stockholders' equity requirement.","Nasdaq will delist on Dec 2, 2025 unless Company requests a hearing panel appeal by Nov 28, 2025.","Moleculin intends to appeal the determination to stay suspension and continue trading under symbol MBRX."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123228,"accession_number":"0001437749-25-034635","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin reports 60% enrollment for first interim unblinding of Phase 3 AML trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["60% of target 45 subjects for first interim unblinding of MIRACLE (R/R AML) trial have consented (as of Nov 4, 2025).","Completion of treatment for first 45 subjects expected Q1 2026; unblinding thereafter.","Blinded response activity tracking within expected range based on historical trial arm responses.","CEO notes strong recruitment momentum despite EU bed shortages.","Annamycin has FDA Fast Track and Orphan Drug designations for R/R AML; patent protection through 2040-2045."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123227,"accession_number":"0001437749-25-034263","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin Biotech Enters Research Agreement with UNC to Evaluate Annamycin for Pancreatic Cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with University of North Carolina at Chapel Hill for investigator-initiated preclinical research on Annamycin for pancreatic cancer.","Moleculin will supply Annamycin; studies will evaluate liposomal Annamycin vs. Doxil in PDAC GEMM models.","CEO Walter Klemp noted Annamycin's high affinity for pancreas and correlation of topoisomerase II upregulation with poor survival.","Preclinical research is grant-funded and dovetails with recently announced investigator-funded clinical trial in pancreatic cancer patients.","Annamycin has Fast Track Status and Orphan Drug Designations from FDA for AML and STS lung mets, and EMA for relapsed/refractory AML."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123226,"accession_number":"0001437749-25-032447","cik":1659617,"company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Moleculin Biotech files 8-K with investor presentation; content not extractable from filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company posted October 2025 investor presentation on its website.","No specific financial results, clinical milestones, or guidance disclosed in the 8-K text itself.","Exhibit 99.1 is an image; no quantitative data available for analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":14301418.490842493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2025-10-30T23:59:59+00:00|123226"}